Back to results
US 2015/0307482 A1Published application
Methods and compositions for inhibiting cnksr1
AssigneePhusis Therapeutics, Inc.
InventorsD. LYNN KIRKPATRICK, MARTIN INDARTE, NATHAN T. IHLE
Life of this patent
Estimating the term…
Abstract
Embodiments include compositions and methods of inhibiting CNKSR1 and methods of identifying inhibitors of CNKSR1.
Claims35
A compound of formula IA:
- wherein
- R is —C1-C4 alkyl, —NO2, —NH2, NHSO2CH3, —C1-C5 cylcloalkyl, or —CF3;
- R2 is H or
- R and R2 combine as
- to form a bicyclic moiety with the carbons to which they are attached;
- R1 is —C(O), —C(O)O(C1-C4alkyl), —C(O)OH, —CH(OH)(CH2)nNH2, —CH(OH), —C(OH)CNO2, —(CH2)nNO2, —CHO, —C(O)NHR3,
- n is 1, 2, 3, or 4;
- R3 is —C1-C4alkyl, —C1-C2 alkyl-C(O)NH2, —S(O)2CH3;
- provided when R is Me, R1 is NOT —C(O)OCH2CH3;
- or a pharmaceutically acceptable salt thereof.
7 more elements
A compound of Formula IIA:
- wherein
- R4 is —H, —C1-C4alkyl,
- R5 is —C1-C4alkyl-OH, —C2-C6alkenyl-OH, —C1-C4allcykl-C(O)—C1-C4alkyl, —C2-C6alkenyl-C(O)—C1-C4alkyl, —C1-C4alkykl-C(O)—C3-C5cycloalkyl, —C2-C6alkenyl-C(O)—C3-C5cycloalkyl,
- R8 is C1-C4alkyl, or —C3-C5 cycloalkyl;
- R7 is H or
- or a pharmaceutically acceptable salt thereof.
3 more elements
A compound of Formula IIIA:
- wherein
- R9 is —H or —C1-C4alkyl;
- R10 is —C(O)O C1-C4alkyl, —C(O)OH,
- R11 is H or C1-C4alkyl;
- R12 is C1-C4alkyl;
- or a pharmaceutically acceptable salt thereof.
3 more elements
A compound of formula IVA:
- wherein R13 is —OH or C1-C4 alkyl;
- R14 is H or C1-C4 alkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.